Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | CD38 | P28907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101972 | 0.94 | CRHR1 (0.33) | NR1H2NR1H3CRHR1PTGESF7 | |
| SCHEMBL4091530 | 0.89 | MAP4K1 (0.38) | NR1H2NR1H3CRHR1PTGES | |
| SCHEMBL4096513 | 0.88 | HRH4 (0.35) | NR1H2NR1H3CRHR1 | |
| SCHEMBL4102310 | 0.87 | CRHR1 (0.33) | NR1H2NR1H3CRHR1HSP90AA1HSP90AB1 | |
| SCHEMBL4098134 | 0.87 | MAP4K1 (0.33) | NR1H2NR1H3CRHR1 | |
| SCHEMBL4102485 | 0.86 | CRHR1 (0.33) | CRHR1 | |
| SCHEMBL4101015 | 0.86 | MAP4K1 (0.32) | — | |
| SCHEMBL4098135 | 0.86 | MAP4K1 (0.32) | — | |
| SCHEMBL4097982 | 0.85 | KDM4E (0.33) | CRHR1 | |
| SCHEMBL4105401 | 0.85 | MAPT (0.34) | NR1H2NR1H3CRHR1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1903045-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234117-A1 | Pyrazolopyrimidine Derivative | MC2R, CRHR1, AVPR2 | NR1H2 389/4885NR1H3 576/4885CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.